Transcept, ARCA: Where Are They Now?
Reverse Merger Interest Dims As IPO Window Creaks Open
By Jennifer Boggs
Monday, February 28, 2011
Back before Ironwood Pharmaceuticals Inc. showed the world that biotechs could make a go at initial public offerings (IPO), the reverse merger temporarily shed its less-than-desirable reputation. It became the exit du jour for private biotechs whose IPO bids were stymied by unfavorable market conditions and needed access to substantial cash.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.